This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Zumutor Biologics Inc.
Zumutor Biologics Inc.
AvenCell Therapeutics, Inc.
Monte Rosa Therapeutics, Inc
Adela, Inc
Massive Bio, Inc.
Incyte Corporation
AVM Biotechnology Inc
Tempus AI
Taproot Health
VitaMed Research LLC
Vector Vitale LLC
Astex Pharmaceuticals, Inc.
Sanguine Biosciences
Sierra Oncology LLC - a GSK company
Blue Note Therapeutics
Celgene
GlaxoSmithKline
AstraZeneca
Celgene
LEO Pharma
AbbVie
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals
Sandoz
Astellas Pharma Inc
Valerio Therapeutics
INSYS Therapeutics Inc
Tesaro, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Titan Pharmaceuticals
Novacea